Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Next Previous
Trial Profile

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PVX108 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions
  • Sponsors Aravax

    • Most Recent Events

    • 01 Jun 2023 According to an Aravax media release, trial of PVX108 follow on from few million investment as part of its series B funding round, led by Australian life science investors, Brandon Capital and Tenmile.
    • 01 Jun 2023 According to an Aravax media release, this trial is led in Australia by regional principal investigator Associate Professor Kirsten Perrett, Population Allergy Group Leader at the Murdoch Children's Research Institute.
    • 01 Jun 2023 According to an Aravax media release, first patient has been dosed in a Phase 2 study (AVX-201) being run by Aravax.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top